Dallah Healthcare Co. vs DaVita Inc.
A head-to-head of Dallah Healthcare Co. (4004) and DaVita Inc. (DVA) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | 4004 | DVA |
|---|---|---|
| Market Cap | 10.78B SAR | $15.21B |
| P/E (TTM) | 20.02 | 21.98 |
| Forward P/E | 20.80 | 11.63 |
| P/S | 2.67 | 0.91 |
| P/B | 2.64 | 15.64 |
| EV/EBITDA | 20.79 | 8.90 |
| Dividend Yield | 1.79% | — |
| Profit Margin | 11.15% | 5.65% |
| Gross Margin | 35.71% | 32.25% |
| Operating Margin | 15.40% | 14.74% |
| Revenue Growth (YoY) | +21.68% | +5.96% |
| FCF Yield | -0.21% | 12.00% |
| Debt / Equity | 94.09 | 1013.79 |
| Current Ratio | 1.20 | 1.42 |
Which is better: Dallah Healthcare Co. or DaVita Inc.?
- ✓Larger by market cap: DaVita Inc.
- ✓Cheaper valuation (lower P/E): Dallah Healthcare Co.
- ✓More profitable (net margin): Dallah Healthcare Co.
- ✓Faster revenue growth: Dallah Healthcare Co.
- ✓Higher free-cash-flow yield: DaVita Inc.
Across 12 available metrics, Dallah Healthcare Co. leads 7–5.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Dallah Healthcare Co. with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.